Left ventricular hypertrophy ECG criteria (Sokolow-Lyon and Cornell) encompass standardized electrocardiographic voltage and repolarization metrics designed to non-invasively identify structural thickening of the left ventricular myocardial wall 1. Because the left ventricle contributes the predominant electrical vector during ventricular depolarization, an increase in its muscle mass generates higher-amplitude electrical potentials recorded across surface leads. Although electrocardiography (ECG) lacks the anatomical resolution of imaging modalities, its ubiquitous availability makes it an essential frontline screening tool for identifying end-organ cardiac damage resulting from chronic systemic hypertension, aortic stenosis, and inherited cardiomyopathies 1.

Etiology & Risk Factors

  • Chronic Systemic Arterial Hypertension: The single most prevalent cause of left ventricular hypertrophy globally, imposing chronic pressure overload that forces the myocardium to adapt by increasing wall thickness1.
  • Valvular Heart Disease: Aortic stenosis creates a fixed outflow obstruction, whereas aortic regurgitation imposes combined pressure and volume overloads, both driving significant ventricular remodeling.
  • Genetic and Inherited Cardiomyopathies: Hypertrophic cardiomyopathy (HCM), frequently caused by autosomal dominant mutations in sarcomeric protein genes (e.g., MYH7, MYBPC3), leads to disproportionate and often asymmetric left ventricular hypertrophy.
  • Metabolic and Storage Disorders: Conditions such as Fabry disease, amyloidosis, and Pompe disease infiltrate or metabolically alter the myocardial interstitium, mimicking or exacerbating hypertrophy.
  • Systemic Risk Factors: Advanced age, male sex, African ancestry, obesity, sedentary lifestyle, and chronic kidney disease significantly increase the incidence and severity of myocardial remodeling.

Pathophysiology

The pathophysiological development of left ventricular hypertrophy begins with a sustained hemodynamic burden—most commonly elevated afterload or wall stress. According to Laplace’s law, wall stress is directly proportional to intraventricular pressure multiplied by chamber radius, and inversely proportional to wall thickness. To normalize this elevated wall stress, cardiomyocytes undergo a compensatory hypertrophic response. At the cellular level, mechanical stretch sensors, neurohormonal activation (specifically the renin-angiotensin-aldosterone system and sympathetic nervous system), and growth factors stimulate protein synthesis and activate fetal gene programs. Myocytes enlarge via parallel addition of sarcomeres, leading to concentric hypertrophy where wall thickness increases without a proportional chamber dilation. Concurrently, fibroblast activation promotes extracellular matrix expansion and interstitial fibrosis. This structural enlargement amplifies the total dipole moment of the left ventricle during ventricular activation, generating exaggerated QRS complex amplitudes that exceed standard electrocardiographic thresholds (such as Sokolow-Lyon and Cornell limits). Furthermore, subendocardial ischemia, delayed repolarization gradients across the thickened myocardial wall, and altered action potential durations manifest as secondary ST-segment depression and T-wave inversion, commonly referred to as the strain pattern.

Left ventricular hypertrophy ECG criteria (Sokolow-Lyon and Cornell) — Pathophysiological Cascade & Clinical Flowchart 1 Trigger / Primary Insult Chronic hemodynamic pressure overload such as systemic arterial hypertension or aortic outflow obstruction. 2 Cellular / Pathophysiological Cascade Increased myocardial wall tension triggering parallel sarcomere replication, fibroblast proliferation, and interstitial fibrosis. 3 Target Organ / Structural Change Concentric or eccentric hypertrophy of the left ventricular myocardium leading to increased muscle mass. 4 Hallmark Clinical & Diagnostic Manifestation Increased electrical vector forces manifested as high-voltage QRS complexes and secondary repolarization changes on surface ECG. 5 Complications if Untreated & Therapeutic Target Progression to heart failure with preserved or reduced ejection fraction, ventricular arrhythmias, and sudden cardiac death; mitigated by blood pressure control and regression of hypertrophy.

Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Patients with early electrocardiographic LVH are frequently asymptomatic, identified incidentally during routine screening or preoperative workups. As hypertrophy progresses and diastolic compliance declines, individuals may present with exertional dyspnoea, orthopnoea, paroxysmal nocturnal dyspnoea, anginal chest pain in the absence of epicardial coronary artery disease (due to microvascular dysfunction and increased oxygen demand), palpitations, presyncope, or overt heart failure symptoms.
  • Physical Examination & Named Clinical Signs: Examination may reveal a sustained, forceful, and laterally displaced apex beat (hyperdynamic or heaving point of maximal impulse). A prominent fourth heart sound (S4 gallop) is frequently audible during diastole, reflecting forceful atrial contraction against a stiff, non-compliant left ventricle. In advanced cases, signs of elevated jugular venous pressure, basal pulmonary crackles, and peripheral oedema indicate decompensated heart failure.

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationTransthoracic echocardiography (TTE) or Cardiac Magnetic Resonance (CMR) demonstrating increased left ventricular mass index (>115 g/m² in men, >95 g/m² in women) and increased relative wall thickness or interventricular septal thickness (>11 mm).
Laboratory PanelElevated serum B-type natriuretic peptide (BNP >100 pg/mL) or NT-proBNP (>300 pg/mL) reflecting myocardial wall stress; elevated high-sensitivity troponin in advanced disease; baseline renal function (creatinine, eGFR) and serum electrolytes prior to initiating guideline-directed medical therapy.
Imaging / Radiology (X-ray, US, CT, MRI)Chest radiography may reveal cardiomegaly with an increased cardiothoracic ratio (>0.5), left ventricular contour rounding, and signs of pulmonary venous hypertension (cephalization of pulmonary vessels, Kerley B lines) in decompensated states.
ECG / Histopathology / ProceduralSurface 12-lead ECG demonstrating fulfilled voltage criteria (Sokolow-Lyon or Cornell) alongside left axis deviation, poor R-wave progression in precordial leads, and lateral ST-T wave strain patterns. Histopathology (when obtained via biopsy) shows myocyte hypertrophy, nuclear hyperchromasia, and interstitial fibrosis.

Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
Sokolow-Lyon Voltage Criterion$SV_1 + RV_5 \text{ or } RV_6 \ge 3.5\text{ mV } (35\text{ mm})$. High specificity (~85–90%) but lower sensitivity (~20–30%); indicates prominent electrical forces generated by thickened left ventricular mass.
Cornell Voltage Criterion (Men)$R_{aVL} + S_{V3} > 2.8\text{ mV } (28\text{ mm})$. Adjusted for greater baseline thoracic impedance in males; superior sensitivity compared to Sokolow-Lyon when combined with a duration product.
Cornell Voltage Criterion (Women)$R_{aVL} + S_{V3} > 2.0\text{ mV } (20\text{ mm})$. Lower threshold accounts for lower average voltage amplitudes in female subjects; enhances diagnostic accuracy across diverse populations.
Romhilt-Estes Point Score SystemScore ≥ 5 points indicates definite LVH; 4 points suggests probable LVH. Incorporates voltage criteria (3 pts), ST-T strain pattern (3 pts with digitalis, 1 pt without), left atrial abnormality (3 pts), left axis deviation (2 pts), QRS duration ≥ 0.09s (1 pt), and intrinsicoid deflection in V5/V6 ≥ 0.05s (1 pt).

Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Left Bundle Branch Block (LBBB)Widened QRS complex ($\ge 120\text{ ms}$), broad notched R waves in lateral leads (I, aVL, V5, V6), and absence of Q waves in lateral leads. LBBB alters ventricular activation sequence, independently generating high voltages that mimic or mask true LVH.
Ventricular Pre-excitation (WPW Syndrome)Presence of a shortened PR interval ($< 120\text{ ms}$), a slurred initial upstroke of the QRS complex (delta wave), and widened QRS duration, distinguishing it from pure anatomical hypertrophy.
Athlete's Heart (Physiologic Hypertrophy)Balanced cavity dilation and wall thickening associated with regular intense athletic conditioning; normal diastolic function, absence of strain pattern, and complete regression upon temporary deconditioning.
Infiltrative Cardiomyopathies (Amyloidosis)Low-voltage QRS complexes on surface ECG despite marked, concentric ventricular wall thickening on echocardiography or CMR, creating a classic discordant voltage-to-mass ratio.

Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: In acute decompensated heart failure precipitated by LVH-induced diastolic dysfunction, immediately administer supplemental oxygen to maintain $SpO_2 \ge 92\%$, place the patient in an upright posture, and administer intravenous loop diuretics (e.g., furosemide 40–80 mg IV bolus) to reduce preload and pulmonary congestion.
  • First-Line Medical / Pharmacological Therapy (with exact adult dosing): Implement rigorous blood pressure control targeting $< 130/80\text{ mmHg}$ using renin-angiotensin-aldosterone system (RAAS) antagonists, which have demonstrated superior efficacy in promoting regression of myocardial hypertrophy. Administer lisinopril starting at 10 mg PO once daily (titrated up to 40 mg daily as tolerated) or losartan starting at 50 mg PO once daily (titrated up to 100 mg daily). Combine with dihydropyridine calcium channel blockers (e.g., amlodipine 5–10 mg PO daily) or thiazide-like diuretics (e.g., chlorthalidone 12.5–25 mg PO daily) if additional blood pressure lowering is required. Beta-blockers (e.g., metoprolol succinate 50–200 mg PO daily) are indicated in the presence of coexistent coronary artery disease, heart failure with reduced ejection fraction, or rate control requirements.
  • Surgical / Interventional Indications: Patients with symptomatic obstructive hypertrophic cardiomyopathy refractory to maximal medical therapy should be evaluated for septal reduction therapy, which includes surgical septal myectomy or percutaneous alcohol septal ablation. Valvular interventions (surgical aortic valve replacement or transcatheter aortic valve replacement) are mandatory when LVH is secondary to severe, symptomatic aortic stenosis.

Complications & Prognosis

  • Heart Failure with Preserved Ejection Fraction (HFpEF): Impaired ventricular relaxation and increased chamber stiffness lead to elevated filling pressures, causing progressive exertional dyspnoea and pulmonary congestion despite a normal ejection fraction 1.
  • Cardiac Arrhythmias: Myocardial scarring, interstitial fibrosis, and altered electrical repolarization predispose patients to atrial fibrillation (significantly increasing stroke risk) as well as malignant ventricular arrhythmias and sudden cardiac death 1,3.
  • Ischemic Stroke & Thromboembolism: Structural atrial remodeling and secondary atrial fibrillation create a high-risk substrate for intracardiac thrombus formation and embolic stroke.
  • Prognosis: The presence of electrocardiographic LVH—particularly when accompanied by a repolarization strain pattern—serves as an independent predictor of adverse cardiovascular morbidity and all-cause mortality, underscoring the critical need for early detection and aggressive blood pressure management 1,3.